Royal Philips Launches THOR IDE Trial for Treating Peripheral Artery Disease
Monday, 4 November 2024, 11:36
Overview of the THOR Trial
Royal Philips has embarked on the pivotal THOR IDE trial, designed specifically to evaluate a combined device for laser atherectomy and intravascular lithotripsy catheter. This innovative trial focuses on patients with complex calcified lesions that are challenging to manage with standard approaches.
Goals of the THOR Trial
- To assess safety and effectiveness of the device in treating peripheral artery disease (PAD).
- To gather evidence on the successful treatment of calcified lesions.
- To involve prominent specialists like Elizabeth Anne Genovese and Craig Walker in the trial's oversight.
Importance for Peripheral Artery Disease Patients
The THOR trial holds significant promise for patients suffering from PAD. Addressing complex lesions with advanced technology may profoundly enhance patient care and treatment outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.